NASDAQ:VNDA Vanda Pharmaceuticals (VNDA) Stock Price, News & Analysis → “Crash Insurance” For Your Retirement (From Unstoppable Prosperity) (Ad) Free VNDA Stock Alerts $5.04 +0.03 (+0.60%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$4.87▼$5.0850-Day Range$3.75▼$5.4852-Week Range$3.30▼$6.76Volume1.38 million shsAverage Volume2.46 million shsMarket Capitalization$293.33 millionP/E Ratio100.82Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Vanda Pharmaceuticals alerts: Email Address Vanda Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy4.17% of Float Sold ShortDividend StrengthN/ASustainability-1.77Upright™ Environmental ScoreNews Sentiment-0.04Based on 15 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.06) to ($0.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.85 out of 5 starsMedical Sector612th out of 921 stocksPharmaceutical Preparations Industry289th out of 428 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Vanda Pharmaceuticals.Read more about Vanda Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.17% of the float of Vanda Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVanda Pharmaceuticals has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vanda Pharmaceuticals has recently increased by 11.11%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVanda Pharmaceuticals does not currently pay a dividend.Dividend GrowthVanda Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVanda Pharmaceuticals has received a 61.95% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Tasimelteon", "Antipsychotics", and "Clinical research services for psychotic disorders" products. See details.Environmental SustainabilityThe Environmental Impact score for Vanda Pharmaceuticals is -1.77. Previous Next 1.1 News and Social Media Coverage News SentimentVanda Pharmaceuticals has a news sentiment score of -0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Vanda Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 12 people have searched for VNDA on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Vanda Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vanda Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.70% of the stock of Vanda Pharmaceuticals is held by insiders.Percentage Held by Institutions88.14% of the stock of Vanda Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vanda Pharmaceuticals' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Vanda Pharmaceuticals are expected to decrease in the coming year, from ($0.06) to ($0.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vanda Pharmaceuticals is 100.82, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 142.67.Price to Earnings Ratio vs. SectorThe P/E ratio of Vanda Pharmaceuticals is 100.82, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 176.55.Price to Book Value per Share RatioVanda Pharmaceuticals has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Vanda Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Crash Insurance” For Your RetirementWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free. About Vanda Pharmaceuticals Stock (NASDAQ:VNDA)Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.Read More VNDA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VNDA Stock News HeadlinesMay 10, 2024 | finance.yahoo.comVanda Pharmaceuticals Reports Mixed Q1 2024 Results, Misses Revenue EstimatesMay 9, 2024 | finance.yahoo.comVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q1 2024 Earnings Call TranscriptMay 10, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.May 9, 2024 | finanznachrichten.deVanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Reports First Quarter 2024 Financial ResultsMay 9, 2024 | finance.yahoo.comVanda Pharmaceuticals Inc (VNDA) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...May 9, 2024 | finance.yahoo.comQ1 2024 Vanda Pharmaceuticals Inc Earnings CallMay 8, 2024 | msn.comVanda Pharmaceuticals GAAP EPS of -$0.07, revenue of $47.46MMay 8, 2024 | markets.businessinsider.comVNDA Stock Earnings: Vanda Pharma Misses EPS, Misses Revenue for Q1 2024May 10, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.May 8, 2024 | prnewswire.comVanda Pharmaceuticals Reports First Quarter 2024 Financial ResultsMay 7, 2024 | finanznachrichten.deVanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future PakMay 7, 2024 | markets.businessinsider.comVanda Pharma Receives Revised Unsolicited Takeover Proposal From Future PakMay 7, 2024 | msn.comVanda Pharmaceuticals up 15% as Future Pak sweetens bidMay 7, 2024 | prnewswire.comVanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future PakMay 7, 2024 | finance.yahoo.comUPDATE 2-Future Pak sweetens take-private offer for Vanda PharmaceuticalsMay 7, 2024 | businesswire.comFuture Pak Increases Bid for Vanda Pharmaceuticals to Include CVRs in Addition to $7.25 to $7.75 Per Share in CashApril 30, 2024 | prnewswire.comVanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024April 25, 2024 | finance.yahoo.comUPDATE 1-Shareholder Capital asks Vanda Pharma's board to reconsider Future Pak's offerApril 25, 2024 | reuters.comShareholder Capital asks Vanda Pharma's board to reconsider Future Pak's offerApril 25, 2024 | finance.yahoo.comShareholder Capital Delivers Letter to Independent Members of the Board of Vanda PharmaceuticalsApril 24, 2024 | finance.yahoo.comVanda Pharmaceuticals (VNDA) Stock Sinks As Market Gains: What You Should KnowApril 22, 2024 | prnewswire.comVanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA LitigationApril 22, 2024 | msn.comUS Supreme Court Declines To Hear Vanda Pharmaceuticals' Case Regarding Invalidation Of Patents For Its Sleep Disorder Drug, HetliozApril 22, 2024 | msn.comU.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patentsApril 22, 2024 | msn.comUS Supreme Court reportedly declines to hear Vanda patent caseApril 19, 2024 | reuters.comButler Hall Capital urges Vanda to engage in sales discussionsApril 18, 2024 | finance.yahoo.comFuture Pak Confirms Proposal to Acquire Vanda Pharmaceuticals for $7.25 to $7.75 Per Share in CashSee More Headlines Receive VNDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/03/2021Today5/10/2024Next Earnings (Estimated)7/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:VNDA CUSIP92165910 CIK1347178 Webwww.vandapharma.com Phone(202) 734-3400Fax202-296-1450Employees203Year Founded2002Profitability EPS (Most Recent Fiscal Year)$0.05 Trailing P/E Ratio98.62 Forward P/E RatioN/A P/E GrowthN/ANet Income$2.51 million Net Margins1.30% Pretax Margin3.29% Return on Equity0.46% Return on Assets0.39% Debt Debt-to-Equity RatioN/A Current Ratio4.94 Quick Ratio4.92 Sales & Book Value Annual Sales$192.64 million Price / Sales1.49 Cash FlowN/A Price / Cash FlowN/A Book Value$9.47 per share Price / Book0.52Miscellaneous Outstanding Shares58,198,000Free Float53,717,000Market Cap$286.92 million OptionableOptionable Beta0.71 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Mihael H. Polymeropoulos M.D. (Age 64)Founder, President, CEO & Chairman of The Board Comp: $1.51MMr. Timothy Williams (Age 48)Senior VP, General Counsel & Secretary Comp: $724.38kMr. Joakim Wijkstrom (Age 58)Senior VP & Chief Marketing Officer Comp: $836.36kMr. Scott L. HowellChief People OfficerKey CompetitorsVerastemNASDAQ:VSTMXOMANASDAQ:XOMAEmergent BioSolutionsNYSE:EBSMerrimack PharmaceuticalsNASDAQ:MACKRigel PharmaceuticalsNASDAQ:RIGLView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 60,504 shares on 5/10/2024Ownership: 5.835%State Board of Administration of Florida Retirement SystemBought 32,902 shares on 5/9/2024Ownership: 0.096%SageView Advisory Group LLCBought 8,249 shares on 5/9/2024Ownership: 0.014%Russell Investments Group Ltd.Sold 8,990 shares on 5/8/2024Ownership: 0.107%Empowered Funds LLCBought 15,215 shares on 5/7/2024Ownership: 0.346%View All Insider TransactionsView All Institutional Transactions VNDA Stock Analysis - Frequently Asked Questions How have VNDA shares performed in 2024? Vanda Pharmaceuticals' stock was trading at $4.22 on January 1st, 2024. Since then, VNDA stock has increased by 19.4% and is now trading at $5.04. View the best growth stocks for 2024 here. When is Vanda Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 25th 2024. View our VNDA earnings forecast. How were Vanda Pharmaceuticals' earnings last quarter? Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) announced its quarterly earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.20 by $0.06. The biopharmaceutical company had revenue of $70.10 million for the quarter, compared to the consensus estimate of $73.50 million. Vanda Pharmaceuticals had a trailing twelve-month return on equity of 0.46% and a net margin of 1.30%. During the same quarter in the prior year, the firm posted $0.11 EPS. What ETFs hold Vanda Pharmaceuticals' stock? ETFs with the largest weight of Vanda Pharmaceuticals (NASDAQ:VNDA) stock in their portfolio include Horizon Kinetics Medical ETF (MEDX) and iShares Neuroscience and Healthcare ETF (IBRN).Invesco Nasdaq Future Gen 200 ETF (QQQS). What is Mihael H. Polymeropoulos' approval rating as Vanda Pharmaceuticals' CEO? 12 employees have rated Vanda Pharmaceuticals Chief Executive Officer Mihael H. Polymeropoulos on Glassdoor.com. Mihael H. Polymeropoulos has an approval rating of 24% among the company's employees. This puts Mihael H. Polymeropoulos in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Vanda Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN), Zogenix (ZGNX), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Array Technologies (ARRY), Micron Technology (MU) and Novavax (NVAX). Who are Vanda Pharmaceuticals' major shareholders? Vanda Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.83%), Assenagon Asset Management S.A. (1.27%), Sei Investments Co. (0.89%), GSA Capital Partners LLP (0.84%), Los Angeles Capital Management LLC (0.75%) and Susquehanna Fundamental Investments LLC (0.48%). Insiders that own company stock include Aranthan Jones II, Joakim Wijkstrom, Kevin Patrick Moran, Melissa Young, Mihael Hristos Polymeropoulos, Phaedra Chrousos, Richard W Dugan, Stephen Ray Mitchell and Timothy Williams. View institutional ownership trends. How do I buy shares of Vanda Pharmaceuticals? Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VNDA) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsCharles Payne Demystifies OptionsUnstoppable ProsperityYou need to know these two things about AI stocks ASAP…InvestorPlaceShocking: One AI startup's revenue could surge 4,735%Manward PressMissed NVDA? Buy this AI stock NOWChaikin AnalyticsGold ManiaStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
